Browse 1 Genital Warts Medical Studies Across 1 Cities
1 Genital Warts Clinics
What Are Genital Warts Clinical Trials?
Genital warts are the most common of all STIs, according to the CDC. These appear as soft growths on the genitals. These warts form because of Human Papillomavirus (HPV)'s low strains, including HPV 11 and HPV 6. Genital warts cause itching, discomfort, and pain.
The HPV infection is more dangerous for individuals with vulvas since high-risk stains could result in cancer of the vulva and cervix.
Why Are Genital Warts Being Studied Through Clinical Trials?
Before the introduction of HPV vaccinations, genital warts annually impacted around 340,000 to 360,000 individuals. This translates to one in every 100 sexually active individuals.
Genital infections, including genital warts, have a prevalence of about 10% to 20%. Moreover, 80% of infected individuals are aged between 17 years and 33 years.
The major risk factors for genital warts and other HPV include immunosuppression, smoking, age, and infections with various HPV types.
What Are The Types of Treatments Available For Genital Warts?
There are multiple treatments available for genital warts, but a dermatologist can determine the right one based on multiple factors, including the location of warts, the number of warts, and the physical health of the patient.
The treatment could include medication or a procedure. Some of the significant medications prescribed for genital warts include:
Some of the procedures to treat genital warts include:
What Are Some Recent Breakthrough Clinical Trials For Genital Warts?
There have been several landmark studies involving genital warts in recent years. Some of the most recent studies are:
2021: A new research revealed the connection between the human leukocyte antigen (HLA) system and genital warts. The results indicate the genetic variants present in the HLA can have an impact on the risk of developing genital warts. This is a breakthrough that can help in producing an effective mRNA vaccine for genital warts.
2020: Verrica Pharmaceuticals found promising results during the Phase 2 CARE-1 VP-102 clinical study, which is a topical therapy using 0.7% cantharidin solution for the treatment of external genital warts in a single-use applicator. The VP-102 attained positive results in the primary and secondary endpoint of complete clearance and reduction of genital warts. The breakthrough results indicate that VP-102 can be given to patients with an effective and well-tolerated treatment option for genital warts.
Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Genital Warts Clinical Trials Research?
Merck Sharp & Dohme LLC is a global healthcare organization that is dedicated to funding clinical trials to find innovative solutions to health disorders, including genital warts, by finding the best prescription medicines, biological therapies, vaccines, and other health products.
Tamir Biotechnology is a biopharmaceutical organization that engages and funds the development and discovery of therapeutic drugs for cancer treatment and HPV treatment, including genital warts.